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In 2011, U.S. Markets for Heart Valve Repair and Replacement Products estimated that roughly 
four million people in the United States are diagnosed with a heart valve disorder annually. And 
in the following year, the American Heart Association reported that approximately 35,000 deaths 
in the US were either directly or indirectly attributed to heart valve disease.  
Diseases of the heart valve are degenerative in nature and therefore progressively worsen 
unbeknownst to the patient until symptoms become clinically relevant. By this time, the valve is 
in such poor condition that complete replacement is often the only effective treatment. Current 
solutions are mechanical and bioprosthetic replacements, but each is associated with its own 
inadequacies. As a result, science is now looking to the promising field of tissue engineering for 
solutions to the limitations of current valve replacement options. A patient-tailored, translational 
approach to heart valve replacement that is safe and effective will expectantly be the result of 
efforts put into this rapidly growing area of research.  
Present experiments hypothesize that the success of tissue engineered heart valves lies in the 
complete recellularization of a scaffold with autologous cells prior to implantation. While 
external cell seeding of the valve to avoid thrombogenicity seems to be the most obvious need, 
additional focus on interstitial recellularization is necessary to obtain a truly biocompatible 
replacement capable of valve remodeling and regeneration. Our short term goal is to obtain a 
fully recellularized, viable valve scaffold. Thus far, infiltration of externally seeded cells into the 
acellular tissue scaffold has been shown to some extent, but has led to many questions concerning 
the effectiveness of those seeding methods. More specifically, there are concerns about the 
characterization of the cell phenotypes found in the interstices of the cusp and their effect on the 





The following document proposes a novel method of cell injection into acellular aortic heart 
valve cusp scaffolds followed by mechanical conditioning as a prerequisite to complete valve 
recellularization that will yield proper valvular interstitial cell phenotype within the construct. 
Present studies have optimized the cellular injection technique, determined appropriate 
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CHAPTER 1:  INTRODUCTION AND BACKGROUND 
1.1 The Impact of Cardiovascular (Valvular) Disease 
In 2011 it was estimated that roughly four million people in the United States were diagnosed 
with a heart valve disorder annually [1]. The prevalence of diseases associated with heart valves 
is astounding and means good business for those in manufacturing. As “the global leader in the 
science of heart valve and hemodynamic monitoring,” Edwards Lifesciences reported impressive 
sales during the 2012 fiscal year so much so that they are projected their 2013 sales of Surgical 
Heart Valve Therapy Devices to be more than $800 million [3].    
Often the only solution when treating degeneration or calcification of heart valves is replacement 
of the entire valve. Current mechanical and bioprosthetic options for heart valve replacement are 
mildly satisfactory; the real promise for complete success in the future of replacements lies with 
tissue engineering. There is much potential in this rapidly advancing field, and these efforts 
continue to be highly funded and researched. Thanks to a surge of interest in cardiovascular tissue 
engineering within recent years, major accomplishments in the field have been recorded and are 
continuously being built upon by those who follow. 
1.2 Relevant Anatomy 
There is no doubt that the aortic valve is the most stressed tissue in the human body, completing 
its open/close cycle over three billion times in a person’s lifetime [5]. With approximately 7200 
liters of blood passing through its opening during the course of a single day, the aortic valve 
experiences great shear flow stresses and tremendous amounts of pressure compared to the other 




Figure 1:  Aortic Heart Valve Cusp Structure 
Physiological arrangement of cusp layers [8] (left), Movat's Pentachrome 
Stain of a fresh (native) cusp [9]:  nuclei stain red, collagen stains yellow, 
elastin stains deep purple to black, GAGs stain blue (right) 
valve is incredible; therefore the structure and tissue that the valve is composed of must be able to 
withstand these mechanical requirements. 
The aortic heart valve has three cusps that form semilunar attachments to the aortic root, which is 
continuous with the structure known as the aortic arch [7]. The aortic annulus is the ‘ring-like’ 
structure that is formed circumferentially around the root as a result of the cusp attachments. 
These structures all provide stabilization for the delicate and thin cusp tissue that is made mostly 
of collagen, elastin, and GAGs. 
The cusp is comprised of three distinct layers: the fibrosa, spongiosa, and ventricularis as seen in 
figure 1. The collagen and elastin components give the cusp its load-bearing properties and 
resiliency, respectively. The cusp’s ability to repeatedly be forced out of shape to open allowing 
blood to flow out of the heart and then return to its closed position to prevent the backflow of 
blood into the heart is facilitated by these matrix components. It is the glycosaminoglycan (GAG) 
inner layer of the cusp that allows for the easy, almost frictionless changes in conformation of the 
valve. This layer acts as the shock absorber to help the valve withstand the constant differences in 













1.3 Heart Valve Disease Etiology & Pathology 
Heart valve disease can be caused by general wear of the tissue, an inflammatory response that is 
initiated by cells in the area, bacterial infections, congenital defects, or other idiopathic origins. 
When analyzing the stresses experienced by the aortic valve, general wear of the valve seems to 
be an obvious cause of degeneration, especially as the world population is living longer. It is also 
understood that the flow of blood through the valve can cause micro-tears in the tissue; these tears 
trigger an inflammatory response by the native valvular cells. Valve destruction can also be 
caused by severe cases of rheumatic disease; endocarditis (inflammation of the endocardium) is 
the result and it leads to scarring and damage of the valve leaflets, once again initiating an 
inflammatory response. This particular cause is overwhelmingly prevalent in developing 
countries and indigenous groups within the developed world [10]. Many of the other causes of 
heart valve disease and degeneration are not fully understood, but solutions must be ready to 
combat them nonetheless. 
Heart valve disease causes the failure of various mechanisms of the valve that must be retained in 
order to provide efficient function. Two of the most prevalent malfunctions are insufficiency (also 
referred to as regurgitation) and stenosis.  Regurgitation is described as the improper closing of 
the valve which then causes blood to flow backwards through the aortic valve and back into the 
heart. Stenosis is classified as the hardening of the valve due to calcium build-up (calcification). 
These defects in the function of the aortic valve can be the cause of other pathologies such as left 
ventricular hypertrophy. This condition of the heart develops due to decreasing insufficiency in 
valve function. The heart must compensate for this decrease in cardiac output by pumping harder 
causing the left ventricle to pump harder and therefore increase in size (like any muscle would 
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when it is over worked). Eventually, if left undiagnosed and untreated, this series of events will 
lead to heart failure and death [11]. 
1.4 Current Treatments 
As previously mentioned, by the time a patient begins noticing symptoms of valve deficiency it is 
after the valve has already undergone major degenerative processes leaving it inadequate to 
satisfy the great requirements of the heart’s total cardiac output. For any pathology that might be 
present there are no effective drug treatments that can be used [5]. In most cases, alternative 
measures are not even considered; doctors opt for the patient to receive a valve replacement. As 
one of the short-term measures that can be used to temporarily relieve the symptoms of valve 
disease, the doctor may suggest balloon valvuloplasty. This procedure is typically regarded as a 
bridge-to-aortic valve replacement and not an end point treatment for any patient. 
A revolutionary new method of heart valve replacement is gaining fast support among all those in 
the medical field. The technique is called Transcatheter Aortic Valve Replacement or TAVR. The 
procedure is innovative because it employs a minimally invasive approach to the replacement of a 
large heart structure. Catheterization is used to insert the non-expanded valve into the femoral 
artery where it is then maneuvered through the vasculature until finally reaching the opening of 
the aortic valve. The replacement valve is forced through the pathologically stenosed valve and 
then deployed by balloon expansion of the outer stent covering. The expansion of the stent forces 
open the stenotic valve, the new valve then secures itself in place by relying on the hard calcium 
deposits to act as anchors. The patient does not need to be put on heart-lung bypass in order to 
replace the valve. (Note: There is also another method to performing this surgery that is referred 
to as transapical, meaning through the apex of the heart.) Currently though, TAVR is only 




Figure 2:  Mechanical Heart Valves 
Starr-Edwards Silastic Ball Valve (left) and  
St. Jude Medical Masters HP Valve (right). 
calcific stenosis. Other valve pathologies would not provide the solid anchoring that is present on 
the calcified valve [7]. 
The most widely used treatment option for heart valve disease is still an Aortic Valve 
Replacement (AVR). This involves the complete removal of the pathologic valve and 
replacement with the new valve. As discussed previously, left ventricular hypertrophy is a result 
of valvular disease; after replacement of the dysfunctional valve the tissue can actually revert 
back to a physiologically appropriate mass. This is one of the most significant and obvious signs 
of effective treatment [5]. Following a valve replacement most patients notice quick 
improvements on their quality of life. 
After a patient has been diagnosed with severe heart valve disease and has been approved for 
AVR it then becomes a discussion of what type of valve will be used. There are mechanical and 
bioprosthetic options that are currently on the market. No matter which valve option a 
patient/doctor chooses there is about a 10-15 year range that the valve is guaranteed to last. The 
goal of all major heart valve manufacturers is to improve the long-term durability of the valves so 
that patients would not have to undergo several surgeries throughout their lifetime [12]. 
1.4.1 Mechanical Heart Valve Replacements 
The first designs of replacement heart 
valves were for mechanical models, with 
major breakthroughs occurring in the 
1950’s to 60’s; researchers made many 
developments  in the field of science and 
engineering during this time and applied 
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them effectively to the clinical need for heart solutions. The ball-in-cage design prevailed for 
many years until the tilting disc’s emergence. Eventually the pyrolytic carbon bileaflet valve was 
designed in the 1970’s and became the ‘gold standard’ for mechanical valve replacement. Since 
St. Jude Medical introduced this pyrolytic carbon valve much of the innovation in this area has 
come to a halt; only minor features of the mechanical valves have evolved over the last forty 
years. 
Some of the early challenges with mechanical valves were related to closing load, material 
fatigue, and cavitation. Transvalvular pressure produced variations in the load experienced by the 
valve which lead to “impact wear” and “friction wear.” These two forces worked to weaken the 
structure of the valve. Also, like any device, material fatigue played a large role in the valve’s 
success or failure. This obstacle was overcome with the evolution of materials; once the switch 
from metal to pyrolytic carbon was made this seemed to solve fatigue issues. The third most 
significant failure mode was cavitation, which is characterized by the formation of microbubbles 
in the blood. The microbubbles can, over time, cause pitting and erosion on the surface of the 
valve. This problem was solved during the 1970’s and 80’s with small engineering design 
changes; since then, no reports of failure of the mechanical valves have been reported around 
those modes of mechanical failure. 
Although mechanical valves are the most durable solution (typically said to last for 20-30 years) 
for heart valve replacements there is still one very large issue that has yet to be completely 
avoided. The thrombogenicity of the artificial surface is cause for much concern. Not only are the 
devices non-biological, they also introduce turbulent flow regimes in the flow of blood. The 
turbulence can activate platelets which in turn initiate the formation of thrombi. To prevent this 




Figure 3:  Bioprosthetic Heart Valves 
Medtronic Freestyle Tissue Valve (left) and 
Edwards Lifesciences Perimount Magna 
(right) 
administration of Warfarin, a drug that minimizes the risk of thrombus formation on the valve 
surface. Because this drug decreases the blood’s ability to coagulate on the valve it also means 
that it prevents coagulation systemically leaving the patient vulnerable to major bleeding events. 
This reliance upon the close monitoring of a potentially dangerous and expensive drug therapy is 
the main factor that has kept mechanical valve replacement out of developing countries [13]. 
1.4.2 Bioprosthetic Heart Valve Replacements 
The solution to the possibility of 
thrombogenicity with mechanical valves 
was solved with the advent of 
bioprosthetic valve (BPV) technology. 
These valves are made from either porcine 
aortic valves or bovine pericardium that 
has been chemically fixed, cross-linking 
the tissue and masking the antigens present in the xenogeneic materials. There is much debate 
between the tissue options and their design features, but thus far most options have shown 
comparable results. Although patients do not have to be on any drug therapy for proper 
functioning of the bioprosthetic valve, their longevity is questionable due to other degenerative 
processes, such as calcification and general wear and tear [13]. BPVs are predicted to last 10-15 
years which is a much lower expectation than that of the mechanical valve [14]. 
The xenogeneic tissues are fixed with a dialdehyde known as glutaraldehyde. This process was 
thought to completely cross-link molecules of the ECM rendering the tissue anti-thrombogenic 
and inhibiting calcification. This however, was not necessarily the case because BPVs were 
shown to be highly calcified upon explantation and the presence of inflammatory cells was seen 
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on not only the surface of the valve but also infiltrating into the tissue. Some of the issues with 
inflammation may be due to the tissue still eliciting an immunogenic response by the host. During 
the fixation process, if there is insufficient masking of the receptors or glycoproteins in the tissue 
the components would inevitably cause immune response. In more recent years it has been 
determined that higher concentrations of glutaraldehyde can be used to come as close to ensuring 
a complete cross-linking as possible. Researchers then looked into the effects of the higher 
concentration of glutaraldehyde used. The numerous unbound glutaraldehyde molecules that were 
present needed to be extracted because of their tendency to be pro-calcific. By removing these 
free dialdehydes the tissue was made available for the formation of an endothelial layer to 
flourish on the surface of the valve and calcification initiation was delayed [13]. 
The processing of the valves needed to be assessed to find an answer concerning durability after 
the tissue was fixed. The cross-linking of the tissue obviously had an effect on the overall 
strength and mechanical properties of the valve; the valve must rely purely on the integrity of the 
ECM components with no active remodeling occurring when there is valve damage or 
degradation [14]. When the glutaraldehyde cross-links the tissue, the GAG-rich spongiosa layer 
of the cusp loses its ability to reduce the stress throughout the cusp during the open/close cycle. 
With this layer virtually non-functional, the valve begins to wear at a faster rate. The annulus of 
the valve was also affected by fixation because it made the tissue much more ridge. The annulus 
is supposed to be able to dilate as the heart pumps and the valve opens and closes. After the tissue 
in the annulus is cross-linked it loses most of its ability to function properly causing more stress 
on the cusps that are attached to it. 
In a recent Veterans Affairs Study by Mancini et al. a comparison was made of BPVs and 
mechanical valves that looked specifically at mortality and reoperation rates. After 15 years, 
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follow-ups were conducted and it was found that all-cause mortality was lower for the patients 
implanted with the mechanical valves than the BPVs. Also, the reoperation rate was much lower 
for mechanical than BPV. The data all pointed to what some had already concluded, which is that 
as far as long-term durability is concerned the mechanical valve is the superior [15]. 
Although the mechanical valve is more durable and can be projected to last longer, the BPV is 
still the best choice for those patients who cannot be put on anticoagulant regimes. This group 
would include women who are pregnant or are planning to have children and those who may not 
want to be put on drug therapies due to a very active lifestyle. There is a trend of patient 
populations that receive certain valves, such as elderly patients (65 years and older) typically 
receive BPVs because of the reduced chance for calcification, and younger patients/children 
receive mechanical valves due to the decreased number of reoperations required [5]. 
1.5 Tissue Engineering Solutions for Heart Valve Replacements 
Tissue Engineering seeks to make curative solutions for patients who are seeking long-term 
treatment of disease and tissue degeneration. The constructs that are being researched and tested 
are not simply there to try to compensate for the damaged tissue, the aim is create an actual living 
tissue that can be implanted into a human that will, from that point on, grow and remodel. There 
are five main approaches to heart valve tissue engineering which have been seen as the main 
focus in more recent research:  1) forming a tissue through in vitro, bioreactor conditioning by 
seeding cells on some type of biodegradable scaffold; 2) seeding cells on natural biodegradable 
scaffolds; 3) implanting degradable tissues that are to be remodeled by native cells (also referred 
to as guided tissue regeneration); 4) implanting a decellularized valve scaffold; 5) processes that 
aim to generate tissues in vivo through native pathophysiological conditions [16]. 
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The focus of the current project is in approach 1 as listed above. Referencing the Tissue 
Engineering Paradigm found in figure 4, the first step is to consider is the appropriate cell type 
with which to seed the scaffold. Cells can either be obtained from fully differentiated sources or 
stem cell populations. The possibilities for research using embryonic are limited due to 
government policy, ethical debates, and social stigmas. This is why investigation into alternative 
sources has led to great promise in adult stem cells. Several of the cell sources that are promising 
are vascular-derived cells, bone marrow-derived cells, umbilical cord-derived cells, and adipose-
derived stem cells [17]. Most of these cell sources have been shown to differentiate into many 
cell types, making them pluripotent and useful for the application of tissue engineering. 
Next is the need to develop an appropriate scaffold that will support either cells seeded externally 
and internally or cells that infiltrate from the patient’s surrounding native tissues. The scaffold 
must also be able to perform mechanically in order to withstand the tremendous number of cycles 
that it is to be put through once implanted into the body. Many different types of scaffolds have 
been researched and tested, including, allogeneic (human) or xenogeneic (animal) tissues. These 
are constructs made up of ECM components or are polymer-based structures. When using human 
and animal tissues, a process called decellularization is employed to remove the native cells from 
the valve. This is a process that involves a series of detergent washes that ‘clean out’ the cells, 
leaving only the ECM components (i.e. collagen, elastin, laminin, etc.). These techniques must be 







Figure 4:  Tissue Engineering 
Paradigm- Begin by collection 
of lipoaspirate from autologous 
adipose tissue source. Isolate 
and expand adipose-derived 
stem cells. Next an aortic heart 
valve is harvested from porcine 
model and decellularized in 
order to obtain an acellular 
scaffold. Cells are then seeded 
externally and internally to 
obtain a recellularizaed 
construct. Conditioning in the 
bioreactor system is the final 
step prior to implantation of the  





In regards to decellularization, initial data collected by Cryolife, Inc. during in vivo animal 
studies was very promising; the studies were performed using the Synergraft
TM
 tissue engineered 
heart valve. The scaffolds were decellularized porcine aortic heart valves that were implanted into 
sheep in the pulmonary valve position for 150 days. When the valves were explanted the 
researchers observed great host-cell infiltration; valves were repopulated by fibroblast-like cells. 
They also saw that there was no increase in the calcium content of the valve afterwards. The 
research proceeded to clinical trials based on their promising data. Four of the Synergraft
TM
 
valves were implanted into children in the pulmonary position. All seemed well at first, the 
surgery went well and recovery was typical, but after six weeks the first patient died due to 
sudden cardiac arrest. The second patient died one year post-op, again due to sudden cardiac 
arrest. The third patient died within the 7
th
 day of implantation due to the rupture of the graft. And 
lastly, the fourth patient was ordered to have the valve explanted after only two days of 
implantation. Upon review of the explanted valves it was found that the tissues showed extreme 
amounts of inflammation and the cusps were practically non-existent [18]. 
It was later concluded that the valves had not been completely decellularized; there were porcine 
cells still present within the scaffold. This study cast a dark shadow over tissue engineering that is 
still seen today.  It did, however, shed light on areas that needed to be improved. Standards need 
to be established in which a valve can be said to be 100% decellularized so that catastrophic 
failures like those in this study never happen again. Also, this study showed that not all animal 
models are applicable and appropriate to model in vivo conditions of a human, so we must also 
work to discover the best animals for implantation. 
The final stage in the tissue engineering paradigm before implantation in the patient is the 
conditioning of the tissue construct in a bioreactor. Such conditioning devices can be seen 
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throughout cardiovascular research; systems have been used for vascular grafts, myocardial 
replacement tissues, and heart valves. The use of bioreactor tissue conditioning has been shown to 
aid in the development of mechanical strength within the construct and modulate cellular function 
[19]. Refer to section 2.5 for more on mechanotransduction during pre-conditioning of valve 
constructs seeded with cells. 
Moving forward, many realize that innovation in most areas of tissue engineering is coming from 
academia and start-up companies [13]. The valves that are currently available for patient 
implantation are ‘just OK,’ not great. It is tissue engineering that offers truly innovative and 
revolutionary solutions for heart valve replacement. There are challenges (reference Appendix A) 
that will arise from clinical translation of heart valve tissue engineering, but many researchers 






CHAPTER 2:  HEART VALVE TISSUE ENGINEERING, INTERSTITIAL SEEDING, 
AND CELLS 
2.1 Heart Valve Tissue Engineering:  A Shift in Focus 
Heart valve tissue engineering solutions have seen a shift to putting more of an emphasis on 
pediatric applications [16, 19-24]. This may be the first clinical application in which tissue 
engineering replacements are introduced into patients due to the fact that it is the younger 
population who would benefit the most from a construct that is able to grow and remodel as they 
age. Current mechanical and bioprosthetic replacements are assumed to be sufficient for the aging 
population, but neither of these options is reasonable for use in children who would quickly 
outgrow them. In preparation for clinical translation of tissue engineered solutions researchers are 
attempting to shift their research toward materials and methods that would be more easily 
transitioned to use in patients (from section 1.5 and Appendix A).  
Highlighting some of these proactive steps toward clinical translation, more focus has been 
placed on the concerns surrounding patient variation and an effort has been made to determine 
ways in which tissue engineering solutions can adapt to, detect, and combat these differences. 
From patient-to-patient, large variations are seen in the way each person responds to wound 
healing and tissue remodeling. The overall success of a replacement relies on the ability of the 
patient’s own biological processes to aid in the healing and remodeling of the tissue. Research 
into methods of controlling this variability will be fruitful toward the acceptance of the use of 
tissue engineered replacements and proof of efficacy amongst all patient populations.  
The next step toward clinical translation is addressing the set of safety, efficacy, and quality 
control standards by which tissue engineered devices will need to be tested and validated. 
Beginning with safety studies performed in vitro, a standardized bioreactor testing system will 
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need to be established which will be a large undertaking in itself. The tissue engineered solutions 
will also need to undergo performance and functional testing protocols that need to be created and 
agreed upon. And lastly, in vivo preclinical studies need to be designed in such a way that they 
address actual human response to the device. Currently ovine and porcine models are considered 
the most robust in vivo model for heart valve testing. Sheep are generally helpful to use in 
calcification prediction and pigs in thrombogenicity potential [20]. But neither model is reliable 
for comparison in immunological response of the host. Also, the ovine cardiovascular system is 
able to heal more quickly and completely than a human’s so it is difficult to understand the 
wound healing process of the replacement valve fully [16]. Researchers however, do not see these 
concerns and challenges as a deterrent to continuing progress toward the end goal of developing a 
tissue engineered replacement that will undoubtedly revolutionize modern medicine.  
2.2 Previous Interstitial Cellular Seeding/Infiltration Techniques and Outcomes 
Many methods for cell seeding have been tested and reported in literature. One of the more 
commonly seen methods uses decellularized valve scaffolds that are externally seeded with cells 
and dynamically conditioned in vitro with the hope of observing cell infiltration. In Schenke-
Layland et al., cells collected from ovine sources (endothelial cells and myofibroblasts) were 
externally seeded onto decellularized porcine pulmonary valves that were then subjected to a 
maximum of 16 days in a pulsatile bioreactor system. Cell infiltration into the cusps was observed 
after the conditioning period. It would seem as though the myofibroblasts (MF) had in fact been 
able to migrate into the cusp and repopulate the structure. Since the MF was used to seed, the 
cells in the interstices stained positively for both Vimentin and α-SMA [24-25]. When discussing 
the results of the study the researchers admitted that a less invasive approach for cell isolation 
was needed and that they were not sure whether or not the high levels of α-SMA were an 
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indicator of positive tissue remodeling or if it would lead to the beginning of an unfavorable 
pathological response. 
Other groups have developed more novel techniques of infiltration. Cushing et al. reported on the 
method of serum deprivation in order to repopulate an acellular scaffold. They isolated valvular 
interstitial cells (VICs) from porcine aortic cusps and seeded those externally onto acellular 
porcine aortic cusps. The protocol called for recurrent exposure of seeded cells to serum 
deprivation (using media with 5% FBS instead of 15% FBS) [26]. Although they did observe an 
‘accelerated’ cell infiltration, as opposed to infiltration when using a normal serum level, the 
process was still lengthy. Infiltration began around 2 weeks, but the scaffolds were not considered 
fully repopulated until 4 weeks. While the result of obtaining VIC recellularization of the cusps is 
a great outcome, it is one that is not clinically relevant due to the use of an inaccessible cell 
source and the time in which it took to achieve. Another note to be made is that during the 4 
weeks that the study was conducted, the cusps were in no way mechanically stimulated or 
dynamically conditioned. 
Another novel approach to heart valve scaffold seeding is coined the “self-seeding heart valve.” 
The technique developed by Jordan et al. uses antibody surface conjugation as a means to attract 
circulating progenitor cells in vivo to repopulate the scaffold. The group used CD133 antibodies 
that were conjugated to decellularized porcine pulmonary valves. The conjugated valves were 
then transplanted into sheep in the pulmonary position and explanted after 1 and 3 months. Again, 
repopulation of the cusps was observed, but expression of α-SMA was found throughout the cusp 
even after 3 months of implantation [27]. They do not seem to believe that the extensive 
expression of α-SMA will cause any later issues, but as described in the following section, 2.4, α-
SMA may not be what researchers want to see throughout their cusps. Also, no immunological 
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stains were reported; the cells that are staining within the cusp structure could be macrophages or 
other lymphocytes that have infiltrated.  
2.3 Adipose-Derived Stem Cells  
When seeding tissue engineered scaffolds for regenerative medicine the challenge of stem cell 
availability can be one of the most difficult to overcome. Both scientists and clinicians are 
looking for cell sources that are in line with the criteria listed by Gimble et al.:  1) can be found in 
abundant quantities; 2) can be harvested by minimally invasive procedures; 3) can differentiate 
along multiple cell lineage pathways in a regulatable and reproducible manner; 4) can be safely 
and effectively transplanted to either an autologous or allogeneic host; 5) can be manufactured in 
accordance with current Good Manufacturing Practice guidelines [28]. These requirements are 
necessary in order to develop clinically translatable approaches to tissue engineering. Many cell 
sources are ruled out due to very small yield from harvesting, such as bone marrow-derived 
mesenchymal stem cells; out of the 6x10
6
 cells collected it is believed that only 0.001-.01% are 
actually stem cells [29]. Or they are excluded because of the invasive and painful procedures used 
to obtain them. For example, bone marrow collection is an extremely painful procedure and one 
that most patients would not choose if there were a better option. These and many others are 
reasons in which the focus has shifted to investigation into adipose-derived stem cells (ADSCs). 
They are readily available and easy to obtain through routine liposuction procedure. The process 
of ADSC collection, isolation, expansion, and differentiation is displayed in figure 5. Out of 
approximately 1 gram of adipose tissue 2x10
6
 cells can be collected and 10% of those are 
believed to be stem cells [29]. ADSCs are also known to differentiate into a large variety of cell 





Lipoaspirate is first collected from the patient, and then collagenase is added in order to 
enzymatically digest the tissue. Centrifugation of the infranatant isolates the stromal 
vascular fraction (SVF) from the supernatant. The ADSCs can then be plated and 
expanded. ADSCs have been shown to differentiate into many cell types [29]. 










Figure 6:  Valvular Interstitial Cell Phenotypes – Solid arrows depict the 
transitions that are currently understood. Hatched arrows depict possible 
transitions for which there is currently no solid evidence [28]. 
2.4 Valvular Interstitial Cells 
Within in the last decade much has been hypothesized and/or discovered about valvular 
interstitial cells (VICs) and their function within the heart valve cusps. The valvular interstitial 
cell is the most prevalent cell type in the heart valve; the heart valve is also the only location in 
the body in which VICs are found. They function to maintain valve structure and they aid in 
repair and remodeling of the cusp microstructure. The repair function of the VIC is only initiated 
after some type of trauma or exposure of the cusps to abnormal flow.  
Avrum Gotlieb’s group has proposed one of the more popular opinions on VICs. They claim that 
VIC phenotypes can be organized into five groups according to their function:  embryonic 
progenitor endothelial/mesenchymal cells, quiescent (qVIC), activated (aVIC), progenitor 
(pVIC), and osteoblastic (obVIC). qVICs are the cells that are found in the adult valve that 
participate in the maintenance of normal valve physiology; they are believed to maintain the 
characteristic avascularity of the cusp structure by inhibiting angiogenesis. aVICs regulate 
pathological responses that occur in valve disease and injury. pVICs are believed to be a 
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population of cells that play an important role in valve repair. obVICs are the cells that are 
present in calcific valve pathologies; they regulate chondrogenesis and osteogenesis [28]. 
“The pathogenesis of cardiac valve disease correlates with the emergence of muscle-like 
fibroblasts (myofibroblasts).” This quote from Walker et al. uses the word myofibroblast, but in 
accordance with the previous description of VIC phenotypes, this cell type can also be termed an 
aVIC (activated VIC). In all pathologies of the heart valve, for example, degeneration and 
calcification,  aVICs are found throughout the tissue. And it is α-SMA staining that is the 
hallmark marker to confirm aVIC presence. The results from studies described in section 2.2 and 
many others that report extensive staining of α-SMA in their tissue engineered valves are 
worrisome due to the pathological consequences that could and would be sure to follow with 
prolonged expression of α-SMA. Many researchers in heart valve tissue engineering support the 
understanding that activated VICs are not ideal to have within a cusp that is implanted within a 
patient [30-37]. 
The status of VIC activation is dependent upon the biochemical and biophysical cues within their 
microenvironment [36]. In vitro, molecules such as TGF-β have been shown to induce and 
significantly increase VIC expression of α-SMA and other aVIC markers. A synergistic 
relationship in cell expression of α-SMA is seen when TGF-β exposure is coupled with 
mechanical stress on the cells [37]. In vivo, TGF-β is secreted by VICs in response to injury and 
inflammation of the tissue and therefor leads to the increased presence of aVICs. This mechanism 
is important when considering therapies that can decrease or even reverse pathological activation 
of valvular disease. It is the goal of tissue engineering to design around these two parameters to 
provide conditioning and molecular signaling that is similar to native cusps in order to attain a 
valve that is ready for remodeling and regeneration in vivo. 
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2.5 Mechanotransduction and the Effect of ECM on Stem Cell Differentiation 
The use of bioreactor systems to pre-condition cell-seeded constructs is typically seen in most 
tissue engineering approaches. These systems are used to expose seeded cells to varying 
mechanical forces to induce cellular mechanotransduction. When looking specifically at heart 
valves and the valvular interstitial cells within the tissue it is important to mimic the unique 
mechanical environment at this site. Several studies that aimed to recreate the native heart valve 
tissue mechanics have confirmed that applying cyclical mechanical stimulation of cells leads to 
higher rates of cell proliferation, enhanced production of ECM components, and differentiation of 
stem cells to a desired phenotype in vitro [38-40]. 
Mechanical stimulation combined with the presence of extracellular matrix components, such as 
collagen and elastin, encourages a synergistic relationship on improved stem cell differentiation 
and scaffold remodeling. Following the decellularization process ECM components and specific 
binding sites are retained. These features of the scaffold allow for better cell adhesion through 
integrin attachment and signaling to encourage phenotypic changes. The acellular scaffold is able 
to provide a unique niche in which cells can attach, differentiate, proliferate, and lay down 
extracellular matrix. It is therefore the ideal biomaterial to use for tissue engineered heart valves 




CHAPTER 3:  MATERIALS AND METHODS 
3.1 Materials 
Tissue Decellularization 
0.05M NaOH, (0.05% SDS-sodium dodecyl sulfate, 0.5% Triton X-100, 0.5% Na-
Deoxycholate, and 0.2% EDTA, in 10mM TRIS, at pH 7.5) (all chemicals were of the 
highest purity available and obtained from Sigma-Aldrich Corp., Lakewood, NJ) 
DNase – deoxyribonuclease (Sigma, Steinhelm, Germany)  
RNase – ribonuclease (Thermo Fisher Scientific, Waltham, MA) 
High purity 1,2,3,4,6-Penta-O-galloyl-beta-D-glucose (penta-galloyl glucose, PGG) was 
a generous gift from N.V. Ajinomoto OmniChem S.A., Wetteren, Belgium 
(www.omnichem.be) 
Neutralization 
Neutralization Solution (DMEM, 50% FBS, 1%PSA) 
DMEM - Dulbecco’s Modification of Eagle’s Medium (Corning cellgro®, Manassas, 
VA) 
FBS - Fetal Bovine Serum (Atlanta Biological, Atlanta, GA) 
PSA - Penicillin, Streptomycin, Amphotericin B (Corning cellgro®, Manassas, VA) 
Cell Culture 
hADSC – human adipose-derived stem cell (Invitrogen, Carlsbad, CA) 
Complete MesenPRO RS
TM
 Medium:  MesenPRO RS
TM
 Basal Medium and MesenPRO 
RS
TM
 Growth Supplement (Life Technologies
TM
, Carlsbad, CA) 
Trypsin EDTA (Corning cellgro®, Manassas, VA) 
Cell Scepter (EMD Millipore, Darmstadt, Germany) 
Interstitial Cellular Seeding 
Seeding Solution (DMEM, 10% FBS, and 1% PSA) 
33G needles (Hamilton Company, Reno, NV) 




DMEM, 10% FBS, and 1% PSA 
Rotator (developed by Richard Pascal, manufactured by Clemson University Machining 
and Technical Services) 
Bioreactor (developed by Lee Sierad, manufactured by Clemson University Machining 
and Technical Services) 
Histology 
4% paraformaldehyde (Electron Microscopy Services, Hatfield, PA) 
Hematoxylin & Eosin (H&E) Stain (Thermo Fisher Scientific, Waltham, MA) 
DAPI (4’-6-Diamidino-2-phenylindole) Nucleic Acid Stain (Life Technologies
TM
, 
Carlsbad, CA) and the Vectashield HardSet
TM
 Mounting Medium with DAPI (Vector 
Laboratories, Inc., Burlingame, CA) 
Movat’s Pentachrome (Poly Scientific R&D Corp., Bay Shore, NY) 
Immunohistochemistry (IHC) antibodies:  α-SMA #ab5694, Vimentin #ab92547, prolyl-
4-hydroxylase (P4HA3) #ab101657 (Abcam, Cambridge, MA) 
Vectastain Elite Kit and ABC diaminobenzidine tetrahydrocholoride peroxidase substrate 
kit (Vector Laboratories, Burlingame, CA) 
Microscope/Camera (Zeiss Axiovert 40CFL microscope using AxioVision Release 4.6.3 




















3.2 Methods Overview 








3.3 Experimental Methods 
3.3.1 Valve Collection and Cleaning 
Aortic valves were harvested from porcine hearts donated by Snow Creek Meat Processing Plant. 
The aortic valve was dissected out of the heart in such a way as to maintain excess tissue above 
and below the annulus of the valve. Tissue on the ventricular side of the valve (portions of the 
mitral valve and surrounding muscle) was needed in order to secure the valve within mounting 
rings. A large portion of the ascending aorta was also retained for securement in decellularization 
and conditioning processes. It is important to note that this additional tissue would also serve as a 
clinical means of suturing the tissue engineered valve into the patient. To prepare the valve for 
decellularization the loose fascia was removed from around the outside of the aorta and the 
excess tissue on the ventricular side was thinned to approximately 1.5-3 mm thickness. The 
coronaries were then isolated from the fat and aorta, and ligated with sutures. After trimming and 
ligation, the valves were rinsed in ddH2O and placed into metal mounting rings, as seen in figure 
8. These mounting rings are compatible with all devices used for decellularization and 
conditioning, enabling easy transfer from one system to the other. The valves were stored in 
ddH2O at +4
o


























A. Excess tissue on the ventricular portion of the valve was spread over plastic 
inner ring. It was important to center the opening of the valve in the middle of the 
ring; this would ensure space for the leaflets to open and close properly; B. view 
from aortic side of the valve; C. plastic ring was secured between the metal base 
and tightening ring; D. view from the ventricular side showing proper positioning 
of the valve opening; E. aorta outer legs and aortic inner tube were placed around 
the aorta extending from the valve; F. final secured mounting structure, the aorta 
was then sutured to the plastic inner tube to provide stability to the structure.  
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3.3.2 Valve Decellularization 
Decellularization protocol followed that of previously published, Sierad et al. [42]. Briefly, after 
valves were stored in ddH2O for at least 22 hours the rest of the decellularization process began 
with 2 hour incubation in NaOH to relax the extracellular matrix and prime the matrix for cell 
removal. Followed by three 48 hour washes in decellularization solution, 24 hours in 
DNase/RNase solution to remove nucleic acids, 2 hours in peracetic acid to sterilize the valves 
(after this point all steps were done in sterile conditions with sterile filtered solutions and sterile 
tools), 20 hours in PGG (penta-galloyl glucose) to crosslink the scaffold, and finally stored in 
PBS. All solution changes during the decellularization were separated by adequate rinsing and 
incubation in ddH2O, EtOH, or PBS. During these solution steps, rinses, and incubations the 
valves remained moving in solution on an orbital shaker plate. 
3.3.3 hADSC Culture and Subculture 
To thaw and establish hADSCs, cells were removed from cryopreservation in liquid nitrogen, 
quickly warmed and placed into fresh, warm Complete MesenPRO RS
TM
 Medium. Cells were 
then plated onto a T-175 flask at a density of about 5000 cells per cm
2
. After overnight incubation 
at 37
o
C and 5% CO2 media was replaced. Media change, using Complete MesenPRO RS
TM
 
Medium, occurred every 3-4 days to maintain culture and promote proliferation. 
To subculture hADSCs, media was aspirated from the flask. The surface was rinsed with PBS, 
and then aspirated. Trypsin EDTA that was warmed to 37
o
C was added (at approximately 0.5 mL 
per 10 cm
2
) to detach the cells from the flask. Incubation at 37
o
C in Trypsin EDTA lasted for 
approximately 5 minutes or until majority of the cells had detached. When cells were detached 
Complete MesenPRO Medium was added (approximately 1.5x the volume of Trypsin EDTA 
used). The cell suspension was transferred to a 50 mL conical tube and centrifuged at 210 x g for 
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5 minutes to form the stromal vascular fracture (cell pellet). Complete MesenPRO RS
TM
 
Medium/Trypsin EDTA mixture was aspirated out of the conical, leaving the pellet intact. 
Seeding solution was then used to resuspend the cell pellet for counting. The cell scepter was 
used to count the cells, from which the total number of cells was calculated. Cells were 
resuspended at the desired density (about 5000 cells per cm
2
) and plated. MesenPRO RS
TM
 
Medium was replaced every 3-4 days. 
3.3.4 Neutralization 
After the valves were decellularized and PGG-fixed, they remained in sterile 1x PBS until use. 
Before the valves could be seeded they underwent neutralization incubation. Valves were 
incubated in rotating chambers filled with approximately 120mL of neutralization solution for 12-
22 hours at 37
o
C in the incubator. This step was used to neutralize any unbound PGG and 
enhance the valve scaffold by introducing growth factors prior to seeding. 
3.3.5 Interstitial Cell Seeding 
3.3.5.1 Study 1:  Injection Testing with Carbon Nanoparticles 
Initial injection testing was performed using carbon nanoparticles suspended in DMEM. The 
carbon first needed to be passivated; dry carbon particles were added to PBS , vortexed several 
times, bath sonicated for 5 minutes, then centrifuged at 1500 rpm for 5 minutes. A pellet of 
carbon was formed at the tip of the conical, PBS was removed by vacuum, and pellet was 
resuspended in FBS by vortexing several times. Particles were left in FBS overnight at room 
temperature. The following day the solution was centrifuged at 1500 rpm for 5 minutes. Pellet of 
carbon was formed, FBS removed by vacuum, pellet resuspended in DMEM by vortexing several 
times. This final injection solution was stored in +4
o
C refrigerator until use. 
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Carbon solution was injected using a 30 GA needle either directly into the cusp or indirectly into 
the cusp through the aortic wall. The injection of carbon was an effective method to visualize the 
way in which cells would fill the cusp. Figure 9 shows both macro and micro images of the 
carbon within the scaffold. It was noted that the carbon did not spread in the cusp much farther 
than the injection site. Alternate methods of injection were proposed to obtain more complete 
filling of the cusp, but it was really the separation of the cusp layers that would facilitate the 
































         
 
A. Decellularized porcine aortic heart valve injected with 
carbon nanoparticles (black seen within the cusp structure) 
both directly and indirectly; B. 10x image of carbon particles 
(black particulates within cusp structure) within the 
decellularized cusp structure Movat’s stain: nuclei stain bright 






3.3.5.2 Study 2:  Air Pre-injection Testing 
Pre-injection of air was first attempted using a syringe filled with air, but the pressure generated 
by hand was not sufficient to achieve desired separation of cusp layers. An air pump was tested 
and found that a pressure of 15-20 psi would provide adequate expansion of the cusps. The 
moment that the tip of the needle penetrated the top layer of the cusp the structure expanded and 
separated the cusp layers creating a void in which cell suspension could then be injected. Figure 
10 clearly displays the pockets within the cusp that were created. The base of the cusp was seen 




 A. 2.5x image of the base of the cusp structure; pre-injection of air into the base of the 
cusp inflated and created pockets within the scaffold; B. 10x image displaying cells that 
had been injected after air inflation; C. 10x image displaying size of defect created in the 
scaffold. H&E stain: nuclei stain purple, ECM components stain pink. 




3.3.5.3 Study 3:  Injection Protocol 
All sterile materials were prepared prior to seeding in either Ethylene Oxide or Autoclave at 
121
o
C. Rotating chambers and bioreactors were assembled before any cell work occurred. 
Desired amount of cells (about 4 million per cusp) were passaged and stored in 50 mL conical at 
a concentration of about 8 million cells per mL of seeding solution in the incubator until use. 
Valves that were designated as those that would undergo bioreactor conditioning were secured in 
mounting rings and the aorta sutured to the aorta inner tube. The valves that were designated as 
those that would undergo rotational conditioning were only secured in the mounting rings. Cells 
were removed from the incubator and mixed by inverting the conical. Syringes were pre-loaded 
with 1 mL of cell suspension (approximately ½ mL per cusp, 4 million cells). The pictures in 
figure 11 illustrate the following injection processes. Air pump and 33 GA x 1 ¼ inch needle 
were used to inflate the base and free edge of the cusp with approximately 1-2mL of sterile air. A 
33 GA x 1 ¼ inch needle was then attached to the pre-loaded syringe and cell suspension was 
injected into inflated portions of the cusp (about 0.25 mL per injection site). This same injection 
procedure was repeated for each cusp in each valve. Specified valves were either transferred into 
the bioreactor or rotator for conditioning. The bioreactor was filled with about 700 mL of media 
and the rotating chamber filled with about 120 mL of media. Bioreactor pressures and rotator 
speeds were monitored daily and media was changed every 3-5 days as needed. 
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A. Collected all materials for air injection; B. small bulb pipette and valve that was 
secured in metal mounting rings; C. view when looking down the aorta into the 
valve; D. the bulb pipette was inserted from this side of the aorta in such a manner 
that it filled the cusp; E. once the pipette tip was inside of the cusp, the valve was 
reversed so that the observer was looking at the valve from the ventricular side; F. 
the cusp was then stabilized and stretched outward, gaining better access for 
injection; G. valve and pipette were all be held within one hand, with the other 
kept free to perform the injection; H. pump was attached to a sterile filter and 









J. Close up of stretched cusp; K. needle attached to the tubing was held in opposite 
hand; L. needle tip was carefully advanced into cusp at the base (where the cusp 
meets the aortic wall; M. when cusp structure began to inflate the needle was kept 
in until desired inflation was achieved and then removed; N. needle was then 
detached from the tubing by its luer connection; O. with the valve still in one hand, 
the 1mL syringe was filled with cell suspension; P. filling of the syringe was done 
with one hand, the plunger pulled upwards between thumb and forefinger; Q. 
approximately 0.5mL was used per cusp (4 million cells), one syringe was 









S. Gripped syringe with one finger on the end of the plunger and the others secured 
around the body; T. cell suspension was administered at cusp inflation site; U. 
needle tip was carefully advanced into cusp; V. once the needle was in place the 
plunger was depressed, administering cell suspension into the cusp; W. continued 
to administer suspension until the solution filled the entire inflated base; X. 
approximately 0.25-0.5mL of cell suspension per injection site was used; Y. needle 
tip was then carefully inserted into the tip portion of the cusp; Z. depressed plunger 
to administer approximately 0.25mL of cell suspension and removed needle; AA. 





3.3.6 Dynamic Conditioning 
Bioreactor 
For the first 24 hours that the valves were in the bioreactor pressure was kept at a minimum; just 
enough to have slight opening and closing of the leaflets. Over the following 14 days pressure 
was steadily increased to simulate pulmonic conditions (25-10 mmHg) and 65 beats per minute. 
Valves were kept at these conditions for 10 more days and the study concluded after 24 total 
days within the bioreactor. Media was changed every 3-4 days. 
Rotator 
Immediately after the valve chambers were secured in the rotator the shaker plate to which it was 
attached was started at a level of 2.5 and the rotator was set to speed of 5 rpm. When looking at 
the valves while rotating, movement of the cusps was observed. The speed of rotation was 
increased over 10 days until 10 rpm was reached and the shaker plate was at level 4. The 
remaining 14 days of the study the valves remained at these conditions, and on day 24 the study 








 Figure 12:  Rotator and Bioreactor Conditioning Systems - Rotating chamber 
(developed by Richard Pascal) attached to shaker plate (left) [43]. Clemson Heart Valve 



























A. Valves within seeding chambers; media change was essential for studies 
beyond a 3-4 day time period; in order to remove the media, barb/luer ended 
connectors were placed on claves that were secured to the lid of the chamber, 
this barb was then connected to a vacuum pump which pulled the media out; to 
replace media a 10mL syringe with luer connection was placed onto the second 
clave that was secured to the chamber lid, then media was added; B. Removal of 














Time [day] Speed [rpm] Shaker 
1 5 2.5 
2 5 3 
3 5 3 
4 6 3 
5 6 3 
6 6 3 
7 7 3 
8 8 3.5 
9 8 3.5 
10 9 3.5 
11 10 4 
12 10 4 
13 10 4 
14 10 4 
15 10 4 
16 10 4 
17 10 4 
18 10 4 
19 10 4 
20 10 4 
21 10 4 
22 10 4 
23 10 4 
24 10 4 
 
































































3.3.7 Histological Analysis 
Cusp tissues were dissected out of the valves and placed in 4% PFA. Processing of tissues was 
then done using a Tissue Tek® Processor, followed by embedding, and sectioning (at 4um). 
Orientation of the cusp sections were in the radial direction. All histological analyses were carried 
out according to the product specifications. Brief descriptions of protocols and solutions have 
been listed below. 




DAPI Staining Procedure 
 












Figure 15:  Ovine In Vivo Study – One of the sheep that was implanted with 
an interstitially seeded aortic heart valve. Visible incision and shaved areas 
from where the adipose tissue was retrieved are seen. 
3.3.8 Ovine Model In Vivo Study  
Partnering with researchers and clinicians in Romania, large animal implantation of interstitially 
seeded aortic heart valve constructs studies have begun. Lipoaspirate is collected from the fatty 
tissue around the neck and shoulder blades of the sheep. The adipose-derived stems cells can then 
be isolated and cultured. Valves are decellularized by perfusion method, fixed with PGG, and 
neutralized in DMEM, FBS, PSA solution. The scaffolds are then seeded interstitially by the 
injection method that is displayed in figure 11. The method was taught to several of the people 
who are directly working on the project in Romania, two researchers and one clinician. These 
individuals learned the cell injection technique quickly and have been able to reproduce the 
process on their own. Thus far three sheep have been implanted with injection seeded aortic heart 







CHAPTER 4:  RESULTS 
Figure 16:  Decellularization Analysis 
 
Comparison of fresh cusp tissue (left) and decellularized cusp tissue (right). H&E (top):  
nuclei stain purple, ECM components stain pink. DAPI (2
nd
 from top):  nuclei stain bright 
blue. Movat’s  Pentachrome (3
rd
 from top):  nuclei stain red, collagen stains yellow, 
elastin stains deep purple to black, GAGs stain blue. Gross images of cusps after being 
dissected out of the aortic valve structure (bottom). 
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Figure 17:  Cusp Immediately After Seeding, 24 Days in Bioreactor, and 24 Days in 
Rotator: H&E and DAPI Staining 
 
Images of the cusp immediately after seeding confirm that a large bolus of cells was introduced 
into the structure. From the H&E images of the cusp after 24 days in the bioreactor, there appear 
to be many cells retained within the cusp, but when comparing the DAPI image of that same 
location only a few cell nuclei are visible. Both the H&E and DAPI images of the cusp after 24 






Comparison of seeded scaffolds over various time points; immediately after seeding (left), 
24 days in bioreactor (middle), and 24 days in rotator (right). H&E (top 2 rows):  nuclei 
stain purple, ECM components stain pink. DAPI (bottom):  nuclei stain bright blue. 
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Images depicting the structure of the fibrosa (top) and ventricularis (bottom) after 24 days 
of bioreactor conditioning. H&E (left): nuclei stain purple, ECM components stain pink, 
Movat’s Pentachrome (middle): nuclei stain bright red, collagen stains yellow, elastin 
stains deep purple to black, fibroid/muscle stains red. IHC for Vimentin (right): brown 




Figure 19:  Cusp after 24 Days in the Rotator:  H&E, Movat’s Pentachrome, and IHC 
(Vimentin) Staining 
 
It was observed that the cells created some sort of matrix over the 24 day time period in vitro. The 
higher magnification (40x) panel of the Movat’s Pentachrome stain displays the migration of cells 









Images depicting the structure of the ventricularis (top) and fibrosa (bottom) after 24 days 
of rotator conditioning. H&E (left): nuclei stain purple, ECM components stain pink; 
Movat’s Pentachrome (middle): nuclei stain bright red, collagen stains yellow, elastin 
stains deep purple to black, fibroid/muscle stains red; IHC for Vimentin (right): brown 
staining is positive expression, counterstain with 50/50 hematoxylin. 
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Figure 20:  Fresh Cusp:  IHC for Vimentin, Prolyl-4-hydroxylase, and α-SMA 
 
The cells within the native (fresh) aortic heart valve cusp positively stain for Vimentin throughout 
the entirety of the structure, denoting a fibroblast-like phenotype. Prolyl-4-hydroxylase (P4HA3) 
would be indicative of any new collagen formation in the cusp structure; native cusps express 
little to no P4HA3. As discussed in section 2.4, α-smooth muscle actin (α-SMA) is expressed by 





Immunohistochemistry (IHC) of fresh aortic heart valve cusps; brown staining indicates 
positive expression of the marker of interest. Vimentin (left), Prolyl-4-hydroxylase 
(middle), α-SMA (right).  
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Figure 21:  Cusp after 24 Days in the Bioreactor:  IHC for Vimentin, Prolyl-4-hydroxylase, 
and α-SMA 
 
Staining of Vimentin had an over development of the peroxidase step during staining protocol in 
the mid-region of the section, but the individual cells staining positive for Vimentin can still be 
distinguished due to direct comparison of DAPI images and IHC images; this comparison can be 










Immunohistochemistry (IHC) of cusps after bioreactor conditioning for 24 days; brown 
staining indicates positive expression of the marker of interest. Vimentin (left), Prolyl-4-
hydroxylase (middle), α-SMA (right). 
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Figure 22:  Cusp after 24 Days in the Rotator:  IHC for Vimentin, Prolyl-4-hydroxylase, 
and α-SMA 
 
Positive expression of Vimentin is completely characteristic of that seen in native aortic heart 
valve cusps. No expression of either P4HA3 or α-SMA was observed.
 
IHC of cusps after rotational conditioning for 24 days; brown staining indicates positive 
expression of the marker of interest. Vimentin (left), Prolyl-4-hydroxylase (middle), α-
SMA (right).  
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CHAPTER 5:  DISCUSSION 
5.1 Decellularization 
Histological evaluation, figure 16, showed excellent decellularization of the cusp tissue, which 
was comparable to the results seen in the publication of reference for the decellularization 
procedure [42]. However, this protocol is still insufficient in the complete decellularization of the 
aortic wall, but much promise has been observed in a perfusion decellularization technique. 
Complete decellularization is essential when looking into the clinical use of these constructs. 
Catastrophic failure of the Synergraft
TM
 valve construct was observed in the clinical study 
discussed in Section 1.5, in which the patient’s extreme immune response was triggered by 
inadequate decellularization of the xenogeneic scaffold [18].  
Analysis on if the more robust perfusion decellularization process damages the cusp tissue will 
need to be performed. The ECM structure post-decellularization must still be strong enough to 
withstand cell seeding methods and physiological pressures. A decrease in the mechanical 
properties of the cusps could hinder the proper seeding of cells via the suggested injection 
technique, and could eventually have an impact on cell retention within the structure. 
5.2 Cell Sourcing  
When determining the cell source to be used in tissue engineering research it is important to 
consider the clinical accessibility of obtaining those cells. Sources can be broadly grouped into 
two types, those deemed unreasonable and those that are reasonable cell sources. Examples that 
would be considered unreasonable include:  embryonic, neonatal, and valvular interstitial cells. 
Some of these sources are cause for ethical concern, but many are simply unable to be harvested 
because they are cell types that either are no longer found in adults or cannot not be retrieved 
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from the their location in-situ. For example, heart valves are deemed non-sacrificial tissues due to 
the importance of their function, therefore autologous VICs cannot be collected for 
recellularization purposes [32]. Reasonable cell sources include those that are readily available 
and those that can be derived from readily available sources like induced pluripotent stem cells. 
Any autologous adult cell source would be considered, including:  bone marrow-derived stem 
cells, endothelial cells, fibroblasts, and adipose-derived stem cells. Although bone marrow-
derived and induced-pluripotent are considered reasonable, sources like these and others similar 
can be either very painful for the patient or potentially harmful due to methods used to induce 
their stemness. 
In order to satisfy the inadequacy of using clinically irrelevant cell types, the use of easily 
acquired and readily available ADSCs is very promising due to their recorded ability to 
differentiate into a plethora of cell lineages. Specifically they have been shown to differentiate 
into fibroblast-like cells; expressing markers characteristic of valvular interstitial cells [29]. As 
seen in figure 5, ADSCs are isolated from lipoaspirate that is obtained through route liposuction 
procedures. Also, an abundant number of these cells can be found in relatively small amounts of 
fatty tissue, reducing the amount of total tissue that needs to be collected.  
5.3 Interstitial Cell Seeding Method 
Several research groups have reported successful recellularization of the cusp structure within a 
valve scaffold, but it is important to review the ways in which these groups have fallen short of a 
clinically relevant replacement. Various processes require extensive scaffold preparation, seeding, 
and conditioning protocols. When relying upon seeding approaches by cell infiltration it is the 
long conditioning steps that are needed to observe any cell migration. It has even been noted that 
after weeks of in vitro conditioning cell migration was not accomplished. Looking at groups that 
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have published in vivo repopulation of the interstices of the cusp, they have not completely 
characterized the cell type that has repopulated the structure. Many do not report on results of 
inflammatory or immune response; it is important to know if the cells that are seen in the 
structure are macrophages or other immune cells. Another hallmark of most in vivo data thus far 
is the extensive expression of α-SMA throughout the cusp structure. Even after several months in 
vivo cell expression of α-SMA persists [27], the indication of a myofibroblastic phenotype 
(activated-VIC). The same is seen in the literature on in vitro conditioning resulting in α-SMA 
expression [24, 25]. As discussed in Section 2.4, the persistent expression of α-SMA is correlated 
with the development of valvular pathologies.  
These along with many other reasons is why there is a need to develop a technique that is fast, 
simple, and effective in order to obtain a clinically relevant heart valve replacement. Previous 
attempts by those in this lab group to recellularize the acellular aortic heart cusp in vitro include 
such techniques as, applying a charge across the tissue, chemotaxis, and infiltration of cells into 
the interstices during static and dynamic culture. In testing, each of these techniques was unable 
to achieve cell infiltration through the cusp tissue. This led to the investigation of cell injection 
directly into the cusp structure. As this technique was attempted there was a need to create more 
space between the cusp layers in order to inject a larger bolus of cells. Pre-injection of air into the 
base of the cusp was necessary in order to achieve this separation of the cusp layers. It was 
important to note that although this process did create voids within the cusp, the cells that were 
injected were able to either partially or totally replace the area after conditioning in both the 
bioreactor and rotator. 
As the injection technique was optimized it was found, through both visual observation and 
histological analysis that the best site for inflation and seeding of the cusp was through the 
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ventricularis. Reviewing the anatomy of the cusp structure, Section 1.2, the ventricularis is a very 
elastin-rich region. It was found that this region was the most functionally appropriate area to 
introduce the 33 GA needle; the elastin fibers were able to provide a ‘self-sealing’ capability 
when the needle was retracted. The radially aligned elastin fibers were able to stretch around the 
needle as it was inserted and then relax back after its removal, in essence, recoil to close the 
opening created in the cusp. In comparison, when the needle was inserted from the collagen-rich 
fibrosa region of the cusp, air and cell suspension were able to escape due to the opening that the 
needle made in the structure. It is not only the fact that the collagen bundles are aligned 
circumferentially, but most importantly the collagen structure does not lend itself to having this 
contractile, ‘self-sealing’ capability. 
5.4 Dynamic Conditioning 
During the process of engineering a tissue replacement there exists an overarching concept of 
construct conditioning, whereby the scaffold and cellular components are subjected to 
physiologically relevant conditions (i.e. temperature, pressure, nutrients, etc.) for some prescribed 
time length. Those systems constructed to condition tissues are referred to as bioreactors, as 
discussed in Section 1.5. The conditioning of tissue constructs as a prerequisite for implantation is 
the direction that the field has heavily emphasized in order to create truly functional tissue 
replacements [13, 16, 17, 19, 21, 22, 24, 25, 29-30, 32, 40]. Specifically for heart valve tissue 
engineering, most bioreactor systems attempt to mimic the pulsatile flow of the beating heart. The 
current work compared the conditioning of a pulsatile-flow bioreactor and a rotating system seen 
in figure 12. 
After valves were conditioned in either bioreactor or rotator systems for 24 days the recellularized 
cusp sections resembled the structure of fresh (native) aortic heart valve cusps, and they also had 
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very similar protein and enzyme marker expression/non-expression compared to fresh samples. 
Overall the highest cell retention and what is believed to be cell proliferation was seen in the 
cusps that were subjected to the rotational regime. As seen in figure 17, DAPI confirms that the 
nuclei stained in H&E in the rotated cusp section are in fact nuclei. This same confirmation 
cannot be said for the bioreactor conditioned cusp section; the DAPI shows few nuclei retained 
within the cusp. There is over-staining seen in both the H&E and IHC for Vimentin of the 
bioreactor conditioned cusp that can be very misleading, but this has been recognized and noted 
in the analysis of the histological images. 
IHC analysis suggests that the cells within the cusp of the rotated valve are qVIC-like, expressing 
Vimentin strongly and little to no true staining for α-SMA and prolyl-4-hydroxylase. Direct 
comparison of the image from a native cusp and the seeded/rotator conditioned cusp show few 
differences (figures 20 and 22). The lack of α-SMA expression in the conditioned cusps is 
encouraging because the goal is to achieve the quiescent-VIC phenotype for repopulation of the 
interstices of the cusp. Referring to Gimble et al.’s description of VIC phenotype, Section 2.4, the 







CHAPTER 6:  CONCLUSIONS 
In the tissue engineering of fully recellularized heart valves there is a need to establish a more 
clinically relevant interstitial population of cells and an improved, reproducible technique in 
which to do so. The present work developed an interstitial seeding technique by injection of cells 
directly into the heart valve cusp structure. The injection process was optimized and was shown 
to be a teachable and reproducible method. Through the analysis and comparison of rotational 
and bioreactor conditioning it was found that rotational conditioning of the recellularized valve is 
a better suited technique in which to obtain an implantable construct that more closely resembles 
that of a native heart valve. To support this conclusion we have shown the differentiation of 






CHAPTER 7:  RECOMMENDATIONS 
7.1 Determining Cell Proliferation 
The acellular aortic heart valve scaffold is believed to be a suitable micro-environment in which 
seeded cells can interact and embed themselves. The structure should encourage cell proliferation 
and remodeling of the scaffold. In order to determine whether or not the scaffold provides 
appropriate components and signaling molecules to promote cell proliferation it would be useful 
to stain histological sections for the Ki-67 Antigen. This particular nuclear protein is expressed 
during all active stages of the cell cycle (G1, S, G2, and M-phases), but is not present in resting 
cells (during G0 phase) [46]. Positive expression would indicate that, in fact, over the course of 
the experiment cells had adapted to their micro-environment and the mechanical conditions to 
which they were exposed and began proliferating. This would lead to the confirmation of an 
appropriate cellular response while being conditioned in vitro.  
7.2 Characterization of Material within Conditioned Cusps 
It is important to completely characterize the material that was either created or built up in the 
cusp structure. It is hypothesized to be cellular material from apoptotic cells that simply could not 
be appropriately removed from the structure due to the absence of macrophages within the in 
vitro setup. Several assays can be completed in order to determine nuclear apoptosis of cells in 
the structure; those include but are not limited to:  TUNEL, Annexin V, and Caspase-3. TUNEL 
(terminal deoxynucleotidyl transferase dUTP nick end-labeling) indicates DNA fragmentation, 
Annexin V tags cells that express phosphatidylserine on their surface, and Caspase-3 detects the 
activation of caspase enzymes during apoptosis [47, 48]. Histological sections similar to those 
seen in figures 18-22 need to be evaluated with the assays above. 
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7.3 Injection Point Concerns 
Although it has been proposed that the elastin-rich ventricularis is able to self-seal after injection, 
there may be a need for a more active approach of sealing to ensure that cells will not leak out of 
the cusp when the needle is removed. If this is desired, either BioGlue or some derivative, like 
‘BTglue’ from Tedder et al., could be used to seal the point of injection [40]. These compounds 
combine percentages of bovine serum albumin and glutaraldehyde into an adhesive that is used in 
clinical practice and tissue engineering research. The adhesive could be applied directly onto the 
injection site as the needle is removed from the cusp. It has also been suggested that a very fine 
suture could be used to secure the holes made in the cusp during air and cellular injection. For 
this approach to be applicable a dissection microscope would need to be used to visualize the 
0.21mm (O.D. of needle from Hamilton Company Product Specifications) puncture that the 
needle makes when inserted into the cusp. There is concern surrounding the mechanical function 
of the cusp after employing either of these alternatives; would the cusp still be able to bend and 
stretch as the valve opens and closes, would the adhesive stiffen the cusp, would the extra 
punctures created by the suture cause too much damage, etc.  
7.4 Long-Term In Vitro Studies Combining External and Interstitial Seeding Techniques with 
Rotational Period Followed by Bioreactor Conditioning 
The experiments performed to develop this research project were only run for a maximum of 24 
days with only interstitial seeding being performed. Future studies should attempt to seed the 
aortic heart valve cusps interstitially and externally then condition the construct over the course of 
4-6 weeks; rotational conditioning should occur during the first 3-4 weeks (evaluating at least one 
valve after this time period); followed by bioreactor conditioning for the remaining 2-3 weeks. 
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The final conditioned valves would be compared to static controls, post-rotational conditioning, 
and the studies performed previously.  
7.5 Ovine Model In Vivo Studies 
Preliminarily speaking, the cells that were seen in the valves after rotational conditioning seem to 
be an appropriate representation of physiologically relevant quiescent valvular interstitial cell 
type (positive for Vimentin and negative for α-SMA and P4HA3). If the hypothesis that the 
excess material in the cusp is apoptotic cellular matter, then the only way to clear it out would be 
to introduce the construct to a macrophage containing environment by implanting the conditioned 
construct into an animal model. This in vivo model would serve to test if the interstitial cells 
continue to display qVIC-like phenotype and if the cusp structure can indeed remodel under 
physiological conditions. Valves would be implanted into juvenile sheep in the pulmonary 
position; 6 months and one year time points would be evaluated. 
7.6 Clinical Translation 
Many of the current tissue engineering strategies rely on extensive seeding and conditioning 
protocols that cannot be easily translated into the clinical setting. To reiterate from previous 
statements, many researchers use cell types that are difficult, extremely painful, or even 
impossible to harvest from a living person. A recent article on the clinical translation of 
bioreactor systems into operating rooms aimed to provide patients with an autologous, partially 
recellularized valve replacement within 2-3 days of harvesting cells [21]. Although the group has 
not completely been able to develop all aspects of the protocol thus far; they have come up with 
what seems like a reasonable procedure and timeline for tissue engineering valve replacement to 
be implemented in the clinical setting.  
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The technique of cell harvesting, seeding, and conditioning that is employed in this research 
could be readily manipulated to provide a clinically relevant treatment for patients needing a heart 
valve replacement. Within the clinic, adipose tissue can be harvested quickly and with 
substantially less pain/discomfort relative to other methods of cell collection. From the 
lipoaspirate collected, adipose-derived stem cells can be isolated and plated. As discussed in 
section 2.3, a larger yield of stem cells is possible when using ADSCs as opposed to most other 
cell sources. This is a very important aspect in obtaining a sufficient amount of cells with which 
to seed the valve construct. The cells can then be seeded within the cusp through the injection 
technique shown in figure 11. The seeded valve can immediately be subjected to rotational 
conditioning. The cells within the valve can be maintained with simple media changes every 3-4 
days. The rotating device is small and easily operated. It can also be redesigned to fit into a small 
incubator so it is not an over cumbersome system. The longer the patient is able to wait for the 
replacement, the longer the cells will have to secure themselves in the cusp structure, but if 
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